ABBISKO CAYMAN DL-00001(8ZD) News

Date	Title
May 15	Exploring 3 Undervalued Small Caps In The Asian Market With Insider Activity
May 13	Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congress